Aytu BioPharma Closes $16.6M Stock Offering for EXXUA

Aytu BioScience ( (AYTU) ) has provided an announcement.

On June 9, 2025, Aytu BioPharma announced the closing of an upsized at-the-market public offering of common stock, raising gross proceeds of $16.6 million. The funds are intended to support the commercialization of EXXUA™, a novel FDA-approved treatment for major depressive disorder, which is expected to launch in the fourth quarter of 2025. This strategic move positions Aytu to enter the $22 billion U.S. prescription MDD market, with EXXUA expected to be a significant growth driver due to its unique mechanism and favorable side effect profile.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Spark’s Take on AYTU Stock

According to Spark, TipRanks’ AI Analyst, AYTU is a Neutral.

Aytu BioScience’s overall score is driven by positive earnings call sentiment and promising corporate events, tempered by challenges in financial performance and valuation. The technical analysis indicates potential upside, but profitability and cash flow issues remain key risks.

To see Spark’s full report on AYTU stock, click here.

More about Aytu BioScience

Aytu BioPharma is a pharmaceutical company focused on commercializing novel therapeutics. Its prescription products include EXXUA™ for major depressive disorder (MDD), Adzenys XR-ODT® and Cotempla XR-ODT® for attention deficit hyperactivity disorder (ADHD), and a line of legacy products.

Average Trading Volume: 1,335,477

Technical Sentiment Signal: Sell

Current Market Cap: $12.34M

See more data about AYTU stock on TipRanks’ Stock Analysis page.